Brief: Gracell Biotechnologies Announces China NMPA Clearance For IND Application For Phase 1/2 Clinical Trial Of Fastcar-T GC012F
13/02/2023 12:39
Feb 13 (Reuters) - Gracell Biotechnologies Inc GRCL.O :
* GRACELL BIOTECHNOLOGIES ANNOUNCES CHINA NMPA CLEARANCE FOR
IND
APPLICATION FOR PHASE 1/2 CLINICAL TRIAL OF FASTCAR-T GC012F FOR
TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA
* GRACELL BIOTECHNOLOGIES INC - COMPANY PLANS TO INITIATE
PHASE
1/2 CLINICAL TRIAL IN CHINA IN Q3 OF 2023
* GRACELL BIOTECHNOLOGIES INC - APPROVAL FOLLOWS U.S. FDA
CLEARANCE OF IND APPLICATION FOR BCMA/CD19 DUAL-TARGETING
FASTCAR-T GC012F
* GRACELL BIOTECHNOLOGIES INC - PLANS TO INITIATE A PHASE
1B/2
CLINICAL TRIAL IN U.S. IN Q2 OF 2023
Source text for Eikon: ID:nPn1YZt0sa
Further company coverage: GRCL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gracell Biotechnologies
See all newsBrief: Gracell Biotechnologies Announces Shareholders’ Approval Of Merger Agreement
Brief: Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
Newscasts - UK Day Ahead: European shares start last week of 2023 on strong footing
Live Markets: European futures rise after holiday break
Press Digest: British Business - Dec 27